Ketek's new labeling approved by FDA

Ketek (telithromycin), Sanofi-Aventis' antibiotic, has had new labeling approved by the FDA, including a bolded warning and additional information on liver toxicity and failure, as well as revised recommendations for use in patients with myasthenia gravis. The agency says Ketek's benefits outweigh its potential risks when used according to the labeling.
You must be a registered member of MMM to post a comment.

Next Article in Legal/Regulatory